≡

MAP Kinase Activating Death Domain Protein (MADD)

[Edit]

DENN; IG20; RAB3GEP; Differentially expressed in normal and neoplastic cells; Insulinoma glucagonoma clone 20; Rab3 GDP/GTP exchange factor

MAP Kinase Activating Death Domain Protein (MADD)
CCC F547
HGNC 6766
MGI 2444672
PubMed 9115275
RGD 619922
UniProt Q8WXG6
Wiki MADD
Tumor necrosis factor alpha (TNF-alpha) is a signaling molecule that interacts with one of two receptors on cells targeted for apoptosis. The apoptotic signal is transduced inside these cells by cytoplasmic adaptor proteins.
MADD is a death domain-containing adaptor protein that interacts with the death domain of TNF-alpha receptor 1 to activate mitogen-activated protein kinase (MAPK) and propagate the apoptotic signal. It is membrane-bound and expressed at a higher level in neoplastic cells than in normal cells. Several transcript variants encoding different isoforms have been described for this gene.Highly expressed in fetal brain and kidney; adult testis, ovary, brain and heart. Isoform 5 is constitutively expressed in all tissues. Isoform 7 is expressed in fetal liver and in several cancer cell lines.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF547Hu01 Recombinant MAP Kinase Activating Death Domain Protein (MADD) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for MAP Kinase Activating Death Domain Protein (MADD) CLIA Kit Customized Service Offer
n/a ELISA Kit for MAP Kinase Activating Death Domain Protein (MADD) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant MAP Kinase Activating Death Domain Protein (MADD) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for MAP Kinase Activating Death Domain Protein (MADD) CLIA Kit Customized Service Offer
n/a ELISA Kit for MAP Kinase Activating Death Domain Protein (MADD) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPF547Ra01 Recombinant MAP Kinase Activating Death Domain Protein (MADD) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to MAP Kinase Activating Death Domain Protein (MADD) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for MAP Kinase Activating Death Domain Protein (MADD) CLIA Kit Customized Service Offer
n/a ELISA Kit for MAP Kinase Activating Death Domain Protein (MADD) ELISA Kit Customized Service Offer
  1. "DENN, a novel human gene differentially expressed in normal and neoplastic cells."DNA Seq. 6:263-273(1996) [PubMed] [Europe PMC] [Abstract].
  2. "MADD, a novel death domain protein that interacts with the type 1 tumor necrosis factor receptor and activates mitogen-activated protein kinase."J. Biol. Chem. 272:12069-12075(1997) [PubMed] [Europe PMC] [Abstract]
  3. "The human DENN gene: genomic organization, alternative splicing, and localization to chromosome 11p11.21-p11.22."Genome 41:543-552(1998) [PubMed] [Europe PMC] [Abstract].
  4. "Contrasting effects of IG20 and its splice isoforms, MADD and DENN-SV, on tumor necrosis factor alpha-induced apoptosis and activation of caspase-8 and -3."J. Biol. Chem. 276:47202-47211(2001) [PubMed] [Europe PMC] [Abstract].
  5. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Human chromosome 11 DNA sequence and analysis including novel gene identification." Nature 440:497-500(2006) [PubMed] [Europe PMC] [Abstract]
  7. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract].
  8. "LRDD, a novel leucine rich repeat and death domain containing protein."Biochim. Biophys. Acta 1478:280-288(2000) [PubMed] [Europe PMC] [Abstract]
  9. "Antisense abrogation of DENN expression induces apoptosis of leukemia cells in vitro, causes tumor regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle."Int. J. Cancer 109:24-37(2004) [PubMed] [Europe PMC] [Abstract]
  10. "IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs."Oncogene 23:1076-1087(2004) [PubMed] [Europe PMC] [Abstract]
  11. "Down-regulation of DENN/MADD, a TNF receptor binding protein, correlates with neuronal cell death in Alzheimer's disease brain and hippocampal neurons."Proc. Natl. Acad. Sci. U.S.A. 101:4210-4215(2004) [PubMed] [Europe PMC] [Abstract]
  12. "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
  13. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  14. "Large-scale proteomics analysis of the human kinome."Mol. Cell. Proteomics 8:1751-1764(2009) [PubMed] [Europe PMC] [Abstract]
  15. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  16. "Family-wide characterization of the DENN domain Rab GDP-GTP exchange factors."J. Cell Biol. 191:367-381(2010) [PubMed] [Europe PMC] [Abstract]
  17. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  18. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]